Article

Experts discuss evaluation of pars planitis, intermediate uveitis

Experts discuss strategies for diagnosing intermediate uveitis and pars planitis. This is part one of a two-part series.

Key Points

Editor's Note: Intermediate uveitis, also variably called chronic cyclitis, peripheral uveitis, vitritis, and pars planitis, denotes inflammation localized primarily to the vitreous cavity and accounts for 10% to 15% of cases of uveitis seen at tertiary referral centers. Concomitant vitreous opacities called "snowballs" and pars plana exudates referred to as "snowbanking" also may be present. Intermediate uveitis is, therefore, an anatomic description of the primary location of the inflammation and not a diagnosis per se. In fact, there is no gender or racial predilection, and most patients with intermediate uveitis never have an identified cause for their inflammation.

In North America and Europe, sarcoidosis and multiple sclerosis are the most commonly identified systemic associations, with much less frequent cases resulting from lymphoma, Behcet's disease, Vogt-Koyanagi-Harada (VKH) disease, syphilis, tuberculosis, Lyme disease, HTLV-1 infection, Whipple's disease, Sjögren's syndrome, and HIV infection. Unilateral presentation, particularly in children, should raise suspicion of toxocariasis and diffuse unilateral subacute neuroretinitis (DUSN). Failure to respond to corticosteroid therapy should suggest the possibility of a masquerade syndrome, such as lymphoma, retinitis pigmentosa, amyloidosis, or multiple myeloma.

We asked a panel of authorities to discuss their approach to evaluating and treating this common condition. In part one of this two-part article, the panelists discuss strategies for diagnosing intermediate uveitis and pars planitis. In part two, which will be published in an upcoming issue, they conclude with a discussion of management options.

Carlos Pavesio, MD: Pars planitis is a term used to define the idiopathic form of intermediate uveitis, which occurs more often in children and young adults. It is an important distinction because it implies absence of a systemic association and gives a good picture of possible behavior and prognosis.

Russell W. Read, MD: Pars planitis is a form of intermediate uveitis. All pars planitis is intermediate uveitis, but not all intermediate uveitis is pars planitis. The sine qua non of pars planitis is the presence of snowbanks along the pars plana.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.